Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

血浆ctDNA作为潜在生物标志物用于接受帕博利珠单抗和个体化新表位衍生多肽疫苗治疗的转移性高危上尿路尿路上皮癌患者的纵向监测：病例报告